Scarica l'app Stockscreener
193.94
0.62%
1.20
Dopo l'orario di chiusura:
193.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$192.74
Aprire:
$192.67
Volume 24 ore:
1.09M
Relative Volume:
0.84
Capitalizzazione di mercato:
$28.13B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
18.70
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
-1.52%
1M Prestazione:
-3.93%
6M Prestazione:
-21.59%
1 anno Prestazione:
-22.94%
Intervallo 1D:
$191.85
$195.20
Intervallo di 1 settimana:
$191.65
$197.41
Portata 52W:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? - MSN
Is ResMed stock underperforming the Dow? - MSN
Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Exploring a Potential 38.93% Upside in the Healthcare Innovator - DirectorsTalk Interviews
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
Landscape Capital Management L.L.C. Sells 32,899 Shares of ResMed Inc. $RMD - MarketBeat
ResMed added as new short idea at Hedgeye - MSN
ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure - AD HOC NEWS
Should you continue to hold Resmed stock in your portfolio? - MSN
Milford Funds Ltd. Makes New $28.42 Million Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Why Are ResMed Shares Under Pressure Despite Solid Results? - Kalkine Media
Do Wall Street analysts like ResMed stock? - MSN
ResMed (RMD) Faces Potential 30% Decline Amid Market Concerns - GuruFocus
Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Insider Monkey
Is ResMed Stock Underperforming the Dow? - Barchart.com
ResMed: GLP-1 Threats Are Overstated (NYSE:RMD) - Seeking Alpha
ResMed Inc. $RMD Shares Bought by Deutsche Bank AG - MarketBeat
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
Buy, hold, sell: Resmed, Goodman Group, Westpac shares - The Motley Fool Australia
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed chairman & CEO Michael Farrell sells $968k in stock By Investing.com - Investing.com Australia
ResMed chairman & CEO Michael Farrell sells $968k in stock - Investing.com Nigeria
ResMed Inc. stock (US7611521078): Sleep apnea specialist in focus after recent earnings update - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $968,054.36 in Stock - MarketBeat
Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
LGT Capital Partners LTD. Sells 25,752 Shares of ResMed Inc. $RMD - MarketBeat
BLI Banque de Luxembourg Investments Cuts Stake in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) 10K Form and Latest SEC Filings 2026 - MarketBeat
Down 28% in a year, should I buy the dip on Resmed shares right now? - The Motley Fool Australia
ResMed stock (US7611521078): Revenue growth and sleep-apnea demand stay in focus - AD HOC NEWS
Michael Farrell sells 4,991 RMD shares (NYSE: RMD) via option exercise - Stock Titan
TD Asset Management Inc Has $20.63 Million Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Los Angeles Capital Management LLC - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Makes New $7.93 Million Investment in ResMed Inc. $RMD - MarketBeat
Goldman Sachs Group Inc. Has $235.83 Million Stock Position in ResMed Inc. $RMD - MarketBeat
Cibc World Market Inc. Sells 8,768 Shares of ResMed Inc. $RMD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Valuation Check After Q3 FY2026 Results And Sleep Apnea Demand Update - Sahm
Prudential PLC Raises Position in ResMed Inc. $RMD - MarketBeat
Can ResMed's Sleep Apnea Growth Justify Current Valuation Views? - Kalkine Media
CIBC Asset Management Inc Boosts Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio - Insider Monkey
ResMed Inc. $RMD Shares Sold by Marietta Investment Partners LLC - MarketBeat
ResMed (ASX:RMD) Analysis: What’s Driving Investor Sentiment? - Kalkine
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):